Eli Lilly Acquires 4E Therapeutics
June 16, 2026
Eli Lilly and Company acquired Austin-based neuroscience company 4E Therapeutics to advance its non-opioid chronic pain pipeline. 4E is developing orally available MNK inhibitors targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons, including lead candidate 4ET1103 that entered human Phase 1 trials with a favorable safety profile.
- Buyers
- Eli Lilly and Company
- Targets
- 4E Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- Texas, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.